tetano
Editor, Senior Moderator
Vaccines (Basel). 2018 May 24;6(2). pii: E29. doi: 10.3390/vaccines6020029.
[h=1]Clinical Advances in Viral-Vectored Influenza Vaccines.[/h] Sebastian S[SUP]1[/SUP], Lambe T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza-virus-mediated disease can be associated with high levels of morbidity and mortality, particularly in younger children and older adults. Vaccination is the primary intervention used to curb influenza virus infection, and the WHO recommends immunization for at-risk individuals to mitigate disease. Unfortunately, influenza vaccine composition needs to be updated annually due to antigenic shift and drift in the viral immunogen hemagglutinin (HA). There are a number of alternate vaccination strategies in current development which may circumvent the need for annual re-vaccination, including new platform technologies such as viral-vectored vaccines. We discuss the different vectored vaccines that have been or are currently in clinical trials, with a forward-looking focus on immunogens that may be protective against seasonal and pandemic influenza infection, in the context of viral-vectored vaccines. We also discuss future perspectives and limitations in the field that will need to be addressed before new vaccines can significantly impact disease levels.
[h=4]KEYWORDS:[/h] clinical trials; influenza; viral vectors
PMID: 29794983 DOI: 10.3390/vaccines6020029
[h=1]Clinical Advances in Viral-Vectored Influenza Vaccines.[/h] Sebastian S[SUP]1[/SUP], Lambe T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza-virus-mediated disease can be associated with high levels of morbidity and mortality, particularly in younger children and older adults. Vaccination is the primary intervention used to curb influenza virus infection, and the WHO recommends immunization for at-risk individuals to mitigate disease. Unfortunately, influenza vaccine composition needs to be updated annually due to antigenic shift and drift in the viral immunogen hemagglutinin (HA). There are a number of alternate vaccination strategies in current development which may circumvent the need for annual re-vaccination, including new platform technologies such as viral-vectored vaccines. We discuss the different vectored vaccines that have been or are currently in clinical trials, with a forward-looking focus on immunogens that may be protective against seasonal and pandemic influenza infection, in the context of viral-vectored vaccines. We also discuss future perspectives and limitations in the field that will need to be addressed before new vaccines can significantly impact disease levels.
[h=4]KEYWORDS:[/h] clinical trials; influenza; viral vectors
PMID: 29794983 DOI: 10.3390/vaccines6020029